An international multicenter study analyzed 459 patients who underwent pancreatic resection for adenocarcinoma originating from intraductal papillary mucinous neoplasia (IPMN). Results showed that recurrence was common, with 45.5% experiencing it, including 23.2% with early recurrence within a year. Treatment of recurrence, such as adjuvant chemotherapy and other modalities, significantly improved overall survival, with a median survival of 27.0 months, compared to 14.6 months without treatment. The study highlights the need for vigilance in monitoring IPMN-related adenocarcinoma and considering treatment upon recurrence.
Journal Article by Lucocq J, Hawkyard J (…) Pandanaboyana S et 53 al. in Ann Surg
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.